Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site

PLoS Pathogens

Volumn 11, Issue 5, 2015, Pages

  Crooks, Ema T ^a   Tong, Tommy ^a   Chakrabarti, Bimal ^b,g   Narayan, Kristin ^c,k   Georgiev, Ivelin S ^d   Menis, Sergey ^b   Huang, Xiaoxing ^e   Kulp, Daniel ^b   Osawa, Keiko ^a   Muranaka, Janelle ^c   Stewart Jones, Guillaume ^d,f   Destefano, Joanne ^g   O’Dell, Sijy ^d   LaBranche, Celia ^h   Robinson, James E ⁱ   Montefiori, David C ^h   McKee, Krisha ^d   Du, Sean X ^c   Doria Rose, Nicole ^d   Kwong, Peter D ^d   Mascola, John R ^d   Zhu, Ping ^e   Schief, William R ^b,j   Wyatt, Richard T ^b   Whalen, Robert G ^c   Binley, James M ^a   more..

^a San Diego Biomedical Research Institute   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Altravax Inc ^*  (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e INSTITUTE OF BIOPHYSICS   (China)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^j MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^k Harvard University   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

8ANC195; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; EPITOPE; GLYCAN DERIVATIVE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PG9; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; IMMUNIZATION; MUTAGENESIS; MUTATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; RABBIT; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; ANIMAL; CHEMISTRY; DEFICIENCY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PROTEIN CONFORMATION; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; BINDING SITES; EPITOPES; FEMALE; GUINEA PIGS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; POLYSACCHARIDES; PROTEIN CONFORMATION; RABBITS;

EID: 84930365226     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004932     Document Type: Article

References (90)

1. Schiffner T, Sattentau QJ, Dorrell L, (2013) Development of prophylactic vaccines against HIV-1. Retrovirology 10: 72. doi: 10.1186/1742-4690-10-72 23866844
2. Mascola JR, Montefiori DC, (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28: 413–444. doi: 10.1146/annurev-immunol-030409-101256 20192810
3. Crooks ET, Jiang P, Franti M, Wong S, Zwick MB, et al. (2008) Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 377: 364–378. doi: 10.1016/j.virol.2008.04.045 18539308
4. Kwong PD, Mascola JR, (2012) Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies. Immunity 37: 412–425. doi: 10.1016/j.immuni.2012.08.012 22999947
5. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, et al. (2014) Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514: 455–461. doi: 10.1038/nature13808 25296255
6. McCoy LE, Weiss RA, (2013) Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med 210: 209–223. doi: 10.1084/jem.20121827 23401570
7. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144–4149. 12644702
8. Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, et al. (2013) Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol 87: 7218–7233. doi: 10.1128/JVI.03577-12 23616655
9. Derdeyn CA, Moore PL, Morris L, (2014) Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS 9: 210–216. doi: 10.1097/COH.0000000000000057 24662931
10. Wibmer CK, Bhiman JN, Gray ES, Tumba N, Abdool Karim SS, et al. (2013) Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. PLoS Pathog 9: e1003738. doi: 10.1371/journal.ppat.1003738 24204277
11. Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, et al. (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18: 1688–1692. doi: 10.1038/nm.2985 23086475
12. Kang YK, Andjelic S, Binley JM, Crooks ET, Franti M, et al. (2009) Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 27: 5120–5132. doi: 10.1016/j.vaccine.2009.06.037 19567243
13. Chakrabarti BK, Feng Y, Sharma SK, McKee K, Karlsson Hedestam GB, et al. (2013) Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates. J Virol 87: 13239–13251. doi: 10.1128/JVI.01247-13 24067980
14. Bogers WM, Davis D, Baak I, Kan E, Hofman S, et al. (2008) Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 382: 217–225. doi: 10.1016/j.virol.2008.09.016 18947849
15. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, et al. (2008) Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. Aids 22: 339–348. doi: 10.1097/QAD.0b013e3282f3ca57 18195560
16. Barnett SW, Burke B, Sun Y, Kan E, Legg H, et al. (2010) Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. Journal of virology 84: 5975–5985. doi: 10.1128/JVI.02533-09 20392857
17. Willey R, Nason MC, Nishimura Y, Follmann DA, Martin MA, (2010) Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay. AIDS Res Hum Retroviruses 26: 89–98. doi: 10.1089/aid.2009.0144 20059398
18. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, et al. (1999) Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 5: 204–210. 9930869
19. Quinnan GV, Jr.Yu XF, Lewis MG, Zhang PF, Sutter G, et al. (2005) Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol 79: 3358–3369. 15731230
20. Narayan KM, Agrawal N, Du SX, Muranaka JE, Bauer K, et al. (2013) Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate. PLoS One 8: e52732. doi: 10.1371/journal.pone.0052732 23326351
21. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14: 25–27. 18064037
22. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, et al. (2008) Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. Journal of virology 82: 7369–7378. doi: 10.1128/JVI.00562-08 18495775
23. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, et al. (2013) Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A 110: 18256–18261. doi: 10.1073/pnas.1314351110 24145402
24. Sanders RW (2015) HIV neutralizing antibodies induced by native-like envelope trimers. HIV Vaccines Keystone Symposium 2015.
25. Tong T, Crooks ET, Osawa K, Binley JM, (2012) HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. Journal of virology 86: 3574–3587. doi: 10.1128/JVI.06938-11 22301141
26. Kushnir N, Streatfield SJ, Yusibov V, (2012) Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development. Vaccine 31: 58–83. doi: 10.1016/j.vaccine.2012.10.083 23142589
27. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM, (2010) Virus-like particles in vaccine development. Expert Rev Vaccines 9: 1149–1176. doi: 10.1586/erv.10.115 20923267
28. Tong T, Crooks ET, Osawa K, Robinson JE, Barnes M, et al. (2014) Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques. Virology 456–457: 55–69.
29. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, et al. (2013) Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342: 1484–1490. doi: 10.1126/science.1245627 24179160
30. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, et al. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342: 1477–1483. doi: 10.1126/science.1245625 24179159
31. Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, et al. (2012) Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. Journal of immunology 189: 4816–4824. doi: 10.4049/jimmunol.1202165 23066156
32. McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, et al. (2013) Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 210: 655–663. doi: 10.1084/jem.20122824 23530120
33. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811–817. doi: 10.1126/science.1192819 20616231
34. McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, et al. (2014) HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 346: 1380–1383. doi: 10.1126/science.1259206 25504724
35. Pinheiro A, Lanning D, Alves PC, Mage RG, Knight KL, et al. (2011) Molecular bases of genetic diversity and evolution of the immunoglobulin heavy chain variable region (IGHV) gene locus in leporids. Immunogenetics 63: 397–408. doi: 10.1007/s00251-011-0533-9 21594770
36. Pan R, Sampson JM, Chen Y, Vaine M, Wang S, et al. (2013) Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV-1-infected humans. J Virol 87: 10221–10231. doi: 10.1128/JVI.00843-13 23864637
37. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289. doi: 10.1126/science.1178746 19729618
38. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856–861. doi: 10.1126/science.1187659 20616233
39. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5: e8805. doi: 10.1371/journal.pone.0008805 20098712
40. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633–1637. doi: 10.1126/science.1207227 21764753
41. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, et al. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85: 9998–10009. doi: 10.1128/JVI.05045-11 21795340
42. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466–470. doi: 10.1038/nature10373 21849977
43. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, et al. (2014) Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40: 657–668. doi: 10.1016/j.immuni.2014.04.009 24768347
44. Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, et al. (2012) Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 209: 1469–1479. doi: 10.1084/jem.20120423 22826297
45. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406–412. doi: 10.1038/nature11544 23151583
46. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E, et al. (2014) Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40: 669–680. doi: 10.1016/j.immuni.2014.04.008 24768348
47. Scharf L, Scheid JF, Lee JH, West AP, Jr.Chen C, et al. (2014) Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 7: 785–795. doi: 10.1016/j.celrep.2014.04.001 24767986
48. Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, et al. (2014) Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A 111: 17624–17629. doi: 10.1073/pnas.1415789111 25422458
49. Huang J, Kang BH, Pancera M, Lee JH, Tong T, et al. (2014) Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515: 138–142. doi: 10.1038/nature13601 25186731
50. Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, et al. (2007) A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366: 245–262. 17580087
51. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, et al. (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80: 2515–2528. 16474158
52. Crooks ET, Tong T, Osawa K, Binley JM, (2011) Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. Journal of virology 85: 5825–5839. doi: 10.1128/JVI.00154-11 21471242
53. Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, et al. (2005) Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies 14: 101–113. 16720980
54. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, et al. (2008) Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. Journal of virology 82: 11651–11668. doi: 10.1128/JVI.01762-08 18815292
55. Binley JM, Cayanan CS, Wiley C, Schulke N, Olson WC, et al. (2003) Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 77: 5678–5684. 12719560
56. Doores KJ, Burton DR, (2010) Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84: 10510–10521. doi: 10.1128/JVI.00552-10 20686044
57. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, et al. (2000) A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion- associated structure. J Virol 74: 627–643. 10623724
58. Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, et al. (2007) A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360: 329–340. 17126869
59. Law M, Cardoso RM, Wilson IA, Burton DR, (2007) Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Virol 81: 4272–4285. 17267498
60. Tong T, Osawa K, Robinson JE, Crooks ET, Binley JM, (2013) Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120. J Virol 87: 9233–9249. doi: 10.1128/JVI.01145-13 23740975
61. Alving CR, (2008) 4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues. AIDS 22: 649–651. doi: 10.1097/QAD.0b013e3282f51922 18317008
62. Blish CA, Nguyen MA, Overbaugh J, (2008) Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med 5: e9. doi: 10.1371/journal.pmed.0050009 18177204
63. Shen X, Dennison SM, Liu P, Gao F, Jaeger F, et al. (2010) Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc Natl Acad Sci U S A 107: 5972–5977. doi: 10.1073/pnas.0912381107 20231447
64. Binley JM, Ban YE, Crooks ET, Eggink D, Osawa K, et al. (2010) Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. Journal of virology 84: 5637–5655. doi: 10.1128/JVI.00105-10 20335257
65. Loving R, Sjoberg M, Wu SR, Binley JM, Garoff H, (2013) Inhibition of the HIV-1 spike by single-PG9/16-antibody binding suggests a coordinated-activation model for its three protomeric units. J Virol 87: 7000–7007. doi: 10.1128/JVI.00530-13 23596290
66. Derking R, Ozorowski G, Sliepen K, Yasmeen A, Cupo A, et al. (2015) Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer. PLoS Pathog 11: e1004767. doi: 10.1371/journal.ppat.1004767 25807248
67. Gach JS, Quendler H, Tong T, Narayan KM, Du SX, et al. (2013) A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One 8: e72054. doi: 10.1371/journal.pone.0072054 23991039
68. Shang H, Han X, Shi X, Zuo T, Goldin M, et al. (2011) Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J Biol Chem 286: 14531–14541. doi: 10.1074/jbc.M111.224527 21325278
69. Georgiev IS, Doria-Rose NA, Zhou T, Kwon YD, Staupe RP, et al. (2013) Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340: 751–756. doi: 10.1126/science.1233989 23661761
70. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, et al. (2008) Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82: 638–651. 17959660
71. West AP, Jr.Scharf L, Horwitz J, Klein F, Nussenzweig MC, et al. (2013) Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc Natl Acad Sci U S A 110: 10598–10603. doi: 10.1073/pnas.1309215110 23754383
72. Chuang GY, Acharya P, Schmidt SD, Yang Y, Louder MK, et al. (2013) Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J Virol 87: 10047–10058. doi: 10.1128/JVI.00984-13 23843642
73. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, et al. (2011) A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 3: 94ra71.
74. Schiller J, Chackerian B, (2014) Why HIV Virions Have Low Numbers of Envelope Spikes: Implications for Vaccine Development. PLoS Pathog 10: e1004254. doi: 10.1371/journal.ppat.1004254 25101974
75. Pissani F, Malherbe DC, Schuman JT, Robins H, Park BS, et al. (2014) Improvement of antibody responses by HIV envelope DNA and protein co-immunization. Vaccine 32: 507–513. doi: 10.1016/j.vaccine.2013.11.022 24280279
76. Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, et al. (2013) Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 9: e1003106. doi: 10.1371/journal.ppat.1003106 23300456
77. Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, et al. (2003) Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313: 387–400. 12954207
78. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019–2022. 15044802
79. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, et al. (2005) Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 79: 6528–6531. 15858037
80. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, et al. (2006) Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol 80: 835–844. 16378985
81. Gao F, Bonsignori M, Liao HX, Kumar A, Xia SM, et al. (2014) Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. Cell 158: 481–491. doi: 10.1016/j.cell.2014.06.022 25065977
82. van den Kerkhof TL, Feenstra KA, Euler Z, van Gils MJ, Rijsdijk LW, et al. (2013) HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. Retrovirology 10: 102. doi: 10.1186/1742-4690-10-102 24059682
83. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, et al. (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496: 469–476. doi: 10.1038/nature12053 23552890
84. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, et al. (2014) Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509: 55–62. doi: 10.1038/nature13036 24590074
85. Murphy MK, Yue L, Pan R, Boliar S, Sethi A, et al. (2013) Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. PLoS Pathog 9: e1003173. doi: 10.1371/journal.ppat.1003173 23468623
86. Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, et al. (2014) Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A 111: E738–747. doi: 10.1073/pnas.1319512111 24550318
87. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, et al. (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of a1—>2 mannose residues on the outer face of gp120. J Virol 76: 7306–7321. 12072529
88. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, et al. (2010) Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proceedings of the National Academy of Sciences of the United States of America 107: 1166–1171. doi: 10.1073/pnas.0911004107 20080564
89. Bonomelli C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, et al. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PloS one 6: e23521. doi: 10.1371/journal.pone.0023521 21858152
90. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ, (2009) Jalview Version 2—a multiple sequence alignment editor and analysis workbench. Bioinformatics 25: 1189–1191. doi: 10.1093/bioinformatics/btp033 19151095